Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study.

ABSTRACT:

Background

Predicting serious hematological adverse events (SHAEs) from poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) would allow us to prioritize patients with ovarian cancer at higher risk for more intensive care, ultimately lowering morbidity and preventing them from premature termination of medication.

Objective

This study aimed to explore the risk factors for SHAEs in patients with ovarian cancer receiving PARPi treatment and develop a risk prediction model for such events.

Methods

Prospective clinical data were collected on patients with ovarian cancer who received PARPi treatment at the Guangxi Medical University Affiliated Tumor Hospital from December 2018 to August 2024. They were divided into a SHAE group and a no-SHAE group based on the

SUBMITTER: Lian X 

PROVIDER: S-EPMC12658389 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature